Euro Diagnostica merges with Biomonitor – enters the fields of theranostics and personalized medicine

Euro Diagnostica, a leader in diagnostic solutions for autoimmune diseases, has entered into a merger agreement with Biomonitor, a leading company in theranostics and personalized medicine. Biomonitor’s patented cell-based assay platform iLite™, based on reporter gene technology, can both monitor functional drug activity and detect neutralizing antibodies. This provides a unique and extremely versatile tool for optimizing patient treatment. Moreover, reporter gene technology can be used to customize assay development during different stages of biological/biosimilar development and manufacturing.

“Adding Biomonitor to the well-established diagnostics business of Euro Diagnostica brings us closer to our mission of providing personalized answers to patients. As well as state-of-the-art diagnostics, we can now also offer our customers patient-monitoring solutions plus assay development for new biopharmaceuticals. The merger strengthens our position as a full-service diagnostics partner. We will be an even more active player in the future – in the development of new personalized medicine as well as other key areas of healthcare,” says Else Beth Trautner, CEO of Euro Diagnostica.

“Up until now, Biomonitor has been one of the leading companies in the world offering cell-based assay solutions based on reporter gene technology to both major pharmaceutical and biotechnology companies. Through the merger with Euro Diagnostica, we are now able to provide more specialists, clinical laboratories and pharmaceutical companies with functional activity tests that detect drug activity and neutralizing antibodies on the same platform. Moreover, a platform that is in keeping with the recommendations of both the FDA and EMA.” comments Arsalan Kharazmi, CEO of Biomonitor.

Because expensive pharmaceuticals are sometimes overprescribed, and patients develop neutralizing antibodies that make their treatment less effective, more efficacious drugs and optimized treatment could save millions of dollars every year just in disease areas like multiple sclerosis, rheumatic arthritis, inflammatory and gastrointestinal disease, and cancer.

“Since the whole foundation of personalized medicine is to monitor and consequently optimize treatment efficacy, the need for safe and reliable testing is now greater than ever. Drug development faces the same challenges. In fact, the race to find new improved drugs is longer and tougher than ever. But as effective drug development is based on reliable testing, the optimized solutions that our merged companies can now offer should speed up the progress considerably,” concludes Else Beth Trautner.